港股異動丨基石藥業-B(02616.HK)大漲近11% 舒格利單抗聯合化療呈現更長久無進展生存期
格隆匯7月12日丨基石藥業-B(02616.HK)大漲近11%,報16.48港元,總市值195億港元。

年內有望獲批上市的新藥舒格利單抗(PD-L1)或將給肺癌治療領域帶來重大改變。基石藥業今早公佈了該款藥物用於一線治療IV期非小細胞肺癌(NSCLC)的臨牀研究最新結果。根據延長隨訪時間的數據,舒格利單抗聯合化療,呈現出了更長久的無進展生存期,高於去年8月公佈的期中分析結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.